ライフサイエンスコーパス: variola virus

1 in pathogenicity between vaccinia virus and variola virus.

2 virulence mechanisms of the causative agent, variola virus.

3 dvantage that it can simultaneously identify variola virus.

4 camelpox, cowpox, ectromelia (mousepox), and variola viruses.

5 pitopes are highly conserved in vaccinia and variola viruses.

6 ed genomic DNA from 48 different isolates of variola virus; 25 different strains and isolates of came

7 Whereas the human variola virus and mouse ectromelia virus encode one vTNF

8 eutic intervention against infections by the variola virus and other poxviruses.

9 as a global illness more than 30 years ago, variola virus and other related pathogenic poxviruses, s

10 epitopes are completely conserved among VV, variola viruses, and most mammalian poxviruses, includin

11 concern over the use of pathogens, including variola virus, as biological weapons.

12 hage host range protein, myxoma virus M011L, variola virus B22R, four ankyrin repeat proteins, three

13 rotein, D7L BTB/POZ domain protein, and B22R variola virus B22R-like protein.

14 With genomic DNA purified from variola virus Bangladesh 1975, the limit of detection wa

15 naturally occurring systemic infection with variola virus both lead to the characteristic skin "pox"

16 Of the 43 samples that contained purified variola virus DNA ranging in concentration from 1 fg/ mi

17 Of the 206 samples that contained variola virus DNA ranging in concentrations from 100 fg/

18 Contained within those 322 samples were variola virus DNA, obtained from purified viral preparat

19 Similar to the human pathogen variola virus, ectromelia virus has a limited host range

20 The Poxviridae family members vaccinia and variola virus enter mammalian cells, replicate outside t

21 hat confer cross-protective immunity against variola virus for decades after immunization.

22 e sequences of 24 strains of smallpox virus (variola virus), for rapid characterization of this human

23 lpox) in a scenario involving the release of variola virus from a laboratory, 19 deaths in a human-ve

24 Thus, proteomic screening of variola virus has the potential to uncover modulators of

25 The vaccinia and variola virus homolog sequences predict 94% identical am

26 amino acid differences compared with its B6 variola virus homologue, B6 might be a better choice for

27 ata suggest that a subunit vaccine using the variola virus homologues might exhibit improved protecti

28 interaction, in contrast to results for the Variola virus IL-18BP, which has been shown to primarily

29 erived from virus-infected cell cultures and variola virus-infected tissues; thus, the DNA material c

30 Survivors of variola virus infection demonstrated VV-specific CD4 mem

31 Of 8 individuals with a history of variola virus infection, 1 had a VV-specific IFN- gamma

32 n magnitude to that achieved through natural variola virus infection, and this may explain the notabl

33 ection in nonhuman primates, a surrogate for variola virus infection, were characterized.

34 fection, and 8 individuals with a history of variola virus infection.

35 the disease is essential because its cause, variola virus, is considered a potential biological weap

36 tive genomics of 45 epidemiologically varied variola virus isolates from the past 30 years of the sma

37 the 14-kDa fusion protein gene of each of 14 variola virus isolates of the Russian World Health Organ

38 74-82), which is shared between vaccinia and variola viruses, may be a CD8(+) T-cell epitope of vacci

39 Many pathogenic orthopoxviruses like variola virus, monkeypox virus, and cowpox virus (CPXV),

40 otection of macaques from monkeypox virus, a variola virus ortholog.

41 time polymerase-chain-reaction assay for non-variola virus orthopoxviruses were positive, and DNA seq

42 eins encoded by the ectromelia virus and the variola virus possess E3 ubiquitin ligase activity in bi

43 te that despite the enhanced activity of the variola virus protein, its cofactor activity in the fact

44 protein interaction screening of the unique variola virus proteome by using yeast 2-hybrid screening

45 In this study, we used a variola virus proteome microarray to characterize and di

46 d alone or in combination with inhibitors of variola virus replication.

47 Outbreaks of smallpox (i.e., caused by variola virus) resulted in up to 30% mortality, but thos

48 hed sequencing is required using Marburg and variola virus sequences.

49 Assuming that B6 contains similar variola virus-specific epitopes, our data suggest that a

50 By use of variola virus-specific primers and long-range PCR, 22 ov

51 , we detail the design and validation of two variola virus-specific real-time PCR assays, since previ

52 encing GeneChips for the rapid sequencing of Variola virus strains in the WHO Repository of the Cente

53 ratures (T(m)s) determined for 46 strains of variola virus (T(m)s, 55.9 to 57.8 degrees C) differed s

54 etected among the 116 samples not containing variola virus tested; i.e., the overall specificity of t

55 s the model because it is closely related to variola virus that causes smallpox.

56 jority of the orthopoxviruses, including the variola virus that causes the dreaded smallpox disease,

57 poxviruses such as vaccinia virus (VACV) and variola virus that fail to form inclusions.

58 duce the spread of vaccinia virus as well as variola virus (the causative agent of smallpox) in vitro

59 ited the spread of vaccinia virus as well as variola virus (the causative agent of smallpox) in vitro

60 rus genus, which includes Vaccinia virus and Variola virus (the causative agent of smallpox).

61 monkeypox virus, and the potential biothreat variola virus (the causative agent of smallpox).

62 (OPVs), which include the agent of smallpox (variola virus), the zoonotic monkeypox virus, the vaccin

63 ACV) affords long-lasting protection against variola virus, the agent of smallpox.

64 irus affords long-lasting protection against variola virus, the agent of smallpox.

65 by modified vaccinia virus Ankara as well as variola virus, the agent of smallpox.

66 stablished as the result of the concern that variola virus, the causative agent of smallpox, as well

67 Variola virus, the causative agent of smallpox, enters a

68 Variola virus, the causative agent of smallpox, is a pot

69 Interestingly, CrmB from variola virus, the causative agent of smallpox, is the m

70 Variola virus, the causative agent of smallpox, is the m

71 T-lymphocyte (CTL) epitopes are defined for variola virus, the causative agent of smallpox, or for v

72 MPXV) is an orthopoxvirus closely related to variola virus, the causative agent of smallpox.

73 ved (>90%) in all orthopoxviruses, including variola virus, the causative agent of smallpox.

74 re encoded by all orthopoxviruses, including variola virus, the causative agent of smallpox.

75 use as a vaccine enabled the eradication of variola virus, the etiologic agent of smallpox.

76 The potential use of variola virus, the etiological agent of smallpox, as a b

77 Variola virus, the most virulent member of the genus Ort

78 Prior to the eradication of variola virus, the orthopoxvirus that causes smallpox, o

79 ilarity between the proteins of vaccinia and variola viruses, these new inhibitors are anticipated to

80 man infections on an intermittent basis, and variola virus (VARV) has potential for use as an agent o

81 dae family members monkeypox virus (MPX) and variola virus (VarV) use conserved mechanisms for actin

82 mescale of emergence of the causative agent, variola virus (VARV), and how it evolved in the context

83 Human disease likely attributable to variola virus (VARV), the etiologic agent of smallpox, h

84 O) vaccination campaign in the 1970s and the variola virus was restricted to repositories in the Unit

85 If variola virus were used as a biological weapon, however,

86 Within the family of poxviruses, variola virus (which causes smallpox) is the most pathog

87 is nearly identical in vaccinia virus and in variola virus, which causes smallpox.

88 Immunization against smallpox (variola virus) with Dryvax, a live vaccinia virus (VV),